NCT00543712View on ClinicalTrials.gov

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 5, 2008

Study Completion Date

May 5, 2008

Conditions
Chondrosarcoma
Interventions
DRUG

PRO95780

Intravenous repeating dose

Trial Locations (4)

3002

Peter MacCallum Cancer Centre, Melbourne

77030

MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Center, Santa Monica

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00543712 - A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | Biotech Hunter | Biotech Hunter